|Day's Range||5.56 - 5.76|
|52 Week Range||2.67 - 7.39|
|PE Ratio (TTM)||133.33|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Categories: Yahoo Finance Osiris Therapeutics, Inc. relative valuation is UNDERVALUED and it has a fundamental analysis score of 86. Our analysis is based on comparing Osiris Therapeutics, Inc. with the following peers – Vericel Corporation, Integra LifeSciences Holdings Corporation, Geron Corporation, Johnson & Johnson, Xtant Medical Holdings, Inc., CONMED Corporation, Nektar Therapeutics and Pluristem Therapeutics Inc. (VCEL-US, IART-US, ... Read more (Read more...)
Osiris Therapeutics Inc. stock has received a delisting notice from the Nasdaq Stock Exchange and will be suspended from trading when the market opens Tuesday. The news sent Osiris shares down more than 10 percent Monday morning, trading at $4.66 per share. Osiris did not file its delinquent financial reports with the U.S. Securities Exchange Commission, the company reported Friday.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]